TITLE

Biogenerics in China: An Evolving Industry

AUTHOR(S)
Langer, Eric
PUB. DATE
June 2007
SOURCE
BioPharm International;Jun2007, Vol. 20 Issue 6, p26
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article discusses the implications of rapid development of the biopharmaceutical industry in China. It is stated that the development plays a significant role in the biogenerics industry. Biogenerics move towards regulatory expansion for the presence of a substantial biogenerics industry in the country reflects a growing need to provide healthcare to domestic populations at a reasonable cost.
ACCESSION #
25571675

 

Related Articles

  • Healthy competition.  // CMAJ: Canadian Medical Association Journal;2/3/2009, Vol. 180 Issue 3, p283 

    The article offers information on the competition in the generic drug market in the United States. The federal Competition Bureau reports that business entities in the pharmaceutical sector could expect a healthy competition and increased annual savings. The expected increased annual income...

  • GSK is accused of paying smaller firms to delay generic paroxetine. Dyer, Clare // BMJ: British Medical Journal;4/27/2013, Vol. 346 Issue 7905, p2 

    The article informs that the Great Britain Office of Fair Trading (OFT) has accused the pharmaceutical company GlaxoSmithKline of breaching competition law and abusing its dominant market in the supply of the antidepressant paroxetine.

  • Another loophole exploited by the drug industry. Brunet, Martin D.; Walters, David // BMJ: British Medical Journal;1/26/2013, Vol. 346 Issue 7892, p25 

    A letter to the editor is presented in response to the article “Making Medicines Evergreen” by Hitchings and colleagues in the November 29, 2012 issue.

  • What's happening to cheap generic drugs? Clever business deals lead to big profits on older generic drugs. Kamerow, Douglas // BMJ: British Medical Journal;10/10/2015, Vol. 351 Issue 8028, ph5329 

    The author reflects on why higher prices could not lead other generic manufacturers to follow the same. Topics discussed include how patients can save money on generics, generic drug companies opting to angle for little used but still necessary drugs to market in a new way, and the increased...

  • Pregabalin is only partially effective for neuropathic pain. Gwynn, Jennie // BMJ: British Medical Journal;7/11/2015, Vol. 351 Issue 8016, ph3478 

    A letter to the editor is presented in response to an article about pharmaceutical company Pfizer's effort to defend control of neuropathic pain drug, pregabalin, by A. Jack in the June 8, 2015 issue.

  • Generic drugs in Canada: an examination of tiered pricing. Hollis, Aidan // CMAJ: Canadian Medical Association Journal;10/6/2015, Vol. 187 Issue 14, p1033 

    The author comments on the deal finalized by the Council of the Federation with generic drug manufacturers to reform the reimbursement scheme for generic drugs. Topics covered include the concept of the tiered pricing scheme, the consequences of the ad hoc price reductions pursued by provincial...

  • BUSINESS as UN usual. Zifferblatt, Jon // Pharmaceutical Executive;Feb2011, Vol. 31 Issue 2, p44 

    The article discusses the changes in the pharmaceutical industry in China. After several years of continued growth, it notes that the country's market becomes complex and that investors may face unfortunate business outcomes if they fail to accurately assess such changes and establish a strategy...

  • Two for One. Garcia, Erica // Money;May2004, Vol. 33 Issue 5, p108 

    Generic drugs may be cheaper, but the stocks remain pricey, so snag a hybrid instead. The appeal is that when branded drugs are riding high, generics tend to lag, and vice versa. Our pick: Switzerland's Novartis, which is the world's fifth-largest drugmaker and boasts the second-largest...

  • The other path for follow-ons.  // Nature Biotechnology;Jul2008, Vol. 26 Issue 7, p715 

    This article discusses the possibility that the biopharmaceutical industry will develop competition based on product innovations rather than the development of generics. The licensing of protein synthesis technology by the biopharmaceutical company Teva Pharmaceutical Industries Ltd. to improve...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics